Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 4/20 | 0.68 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.43 |
| ▸ | GLP1R | P43220 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | SNCA | P37840 | 6/20 | 0.39 |
| ▸ | FFAR2 | O15552 | 2/20 | 0.39 |
| ▸ | GIPR | P48546 | 1/20 | 0.37 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4081595 | 0.92 | GCGR (0.80) | GCGRC5AR1GLP1RTMEM97SIGMAR1 | |
| SCHEMBL2651413 | 0.80 | GCGR (0.63) | GCGRC5AR1GLP1RTMEM97SIGMAR1 | |
| SCHEMBL2651408 | 0.80 | GCGR (0.63) | GCGRC5AR1GLP1RTMEM97SIGMAR1 | |
| SCHEMBL2663066 | 0.75 | GCGR (0.67) | GCGRC5AR1GLP1RTMEM97SIGMAR1 | |
| SCHEMBL13800474 | 0.73 | GCGR (0.61) | GCGRGLP1RTMEM97SIGMAR1GIPR | |
| SCHEMBL4086333 | 0.71 | GCGR (0.73) | GCGRTMEM97SIGMAR1GIPR | |
| SCHEMBL4087887 | 0.70 | GCGR (0.52) | GCGRGLP1RTMEM97SIGMAR1GIPR | |
| SCHEMBL2663347 | 0.69 | GCGR (0.56) | GCGRGLP1RTMEM97SIGMAR1 | |
| SCHEMBL13800468 | 0.68 | GCGR (0.53) | GCGRGLP1RSIGMAR1MEN1KMT2A | |
| SCHEMBL13800470 | 0.67 | HDAC1 (0.58) | GCGRGLP1RMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | NOVO NORDISK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | NOVO NORDISK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | NOVO NORDISK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| EP-1183229-B1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK AS (DK) | 2005-10-26 | — | — | EP | disclosed |
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2005-09-15 | — | — | US | disclosed |
| US-6875760-B2 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2005-04-05 | — | — | US | disclosed |
| US-6503949-B1 | Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity | NORO NORDISK A/S (DK) | 2003-01-07 | — | — | US | disclosed |
| WO-2000069810-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | GCGR 3/4885C5AR1 2480/4885GLP1R 1/4885 |
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | GLP1R, GPR119, GCGR | GCGR 3/4885C5AR1 2480/4885GLP1R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.